Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 628 Neoplasm Metastasis 38 HER2-positive Breast Cancer 33 Breast Neoplasms, Male 30 Inflammatory Breast Neoplasms 20 Brain Neoplasms 18 Stomach Neoplasms 16 Neoplasms 16 Carcinoma, Non-Small-Cell Lung 14 Triple Negative Breast Neoplasms 12 Colorectal Neoplasms 10 Pancreatic Neoplasms 9 Endometrial Neoplasms 9 Ovarian Neoplasms 8 Cardiotoxicity 8 Lung Neoplasms 7 Esophageal Neoplasms 7 Breast Diseases 7 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Prostatic Neoplasms 5 Pathologic Complete Response 5 Carcinoma, Ductal, Breast 5 Urinary Bladder Neoplasms 4 Sarcoma 4 HER2-positive Early Breast Cancer 4 HER2 Positive Breast Cancer 4 Carcinoma, Renal Cell 4 Carcinoma, Hepatocellular 4 Thyroid Neoplasms 3

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Osteitis Deformans × Trastuzumab × Breast × Clear all

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡